Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. (2nd January 2022)

• Record Type: Journal Article
• Authors: Ueno, Makoto; Sugimori, Kazuya; Taguri, Masataka; Ohkawa, Shinichi; Kobayashi, Satoshi; Miwa, Haruo; Kaneko, Takashi; Morimoto, Manabu; Yamanaka, Takeharu
• Is Part Of: Nutrition and cancer. Volume 74:Number 1(2022)
• Page Start: 122
• Page End: 130
• Publication Date: 2022-01-02
• Subjects: Cancer -- Periodicals; Nutrition -- Periodicals; Cancer; Nutrition; Periodicals; 616.9940654
• DOI: 10.1080/01635581.2020.1871495
• Languages: English
• ISSNs: 0163-5581

Abstract

Abstract: Background: Pancreatic cancer is often associated with cachexia. It had been reported that eicosapentaenoic acid (EPA) improve cachexia. This study aimed to evaluate the efficacy and safety of gemcitabine with an EPA-enriched oral supplement in patients with advanced pancreatic cancer. Methods: This open-label phase II study consisted of patients (pts) who were randomly categorized into the EPA group (1, 000 mg/m 2 gemcitabine was administered on day 1, 8, and 15, every 4 weeks while an EPA-enriched oral supplement (prosure®, EPA 1.056 mg per pack) was taken daily at the maximum of two packs or the gemcitabine monotherapy group with an allocation ratio of 2:1. The primary endpoint was the evaluation of the 1-year survival estimating 10% addition. Results: Randomized 68 pts were examined (EPA: 45, gemcitabine: 23). The 1-year survival probability of the EPA group was 35% while the gemcitabine group was 19%. The median survival times were 8.2 and 9.7 mo, respectively. The hazard ratio for EPA group was 0.79 [95% CI 0.46–1.37]; ( P = 0.40). The toxicities were mild and insignificant in both groups. More beneficial effects of EPA in survival were observed in men, pancreatic body-tail and low C-reactive protein patients. Conclusion: An EPA-enriched oral supplement may be effective in advanced pancreatic cancer.